Key result
ACE inhibitors, ARBs, and statins may protect against age-related macular degeneration by improving endothelial function.
Answers are grounded in this paper and cite their sources.
In the genesis and later development of age-related macular degeneration (AMD), endothelial dysfunction (ED) has a crucial role. Various medicines (ACE inhibitors, AR blockers, statins, acetylsalicylic acid, trimetazidine, and third generation beta blockers) exert a beneficial effect on endothelial dysfunction or its consequential functional, structural and metabolic disorders. The beneficial effect of a favourable influence on and successful treatment of ED in patients with chronic vascular and cardiovascular diseases has become evidence now. In ED induced by oxidative stress (OS) ACE inhibitors, AR blockers and statins regenerate the lost balance between vasoconstrictors and vasodilators, growth factors and their inhibitors, pro-inflammatory and anti-inflammatory agents, as well as pro-thrombotic and fibrinolytic factors. They inhibit the development of OS and the evolution of its harmful effects. In addition, the AT1-receptor blocker telmisartan, with its peroxisome proliferator-activated rece...
No takes yet. Share an insight, caveat, or question.
Tamás Fischer (2009) conducted a review in Age-related macular degeneration and endothelial dysfunction. Cardiovascular medications targeting endothelial dysfunction (ACE inhibitors, ARBs, statins, aspirin, trimetazidine, third-generation beta-blockers) was evaluated. ACE inhibitors, ARBs, and statins beneficially modulate oxidative stress-induced endothelial dysfunction, offering a potential preventive strategy for age-related macular degeneration.
Synapse has enriched 10 related papers. Consider them for comparative context: